1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Not Only RET but NF1 and Chromosomal Instability Are Seen in Young Patients with Sporadic Medullary Thyroid Carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Context

          Genetic analysis of sporadic medullary thyroid carcinoma (MTC) has revealed somatic variants in RET, RAS, and occasionally other genes. However, around 20% of patients with sporadic MTC lack a known genetic driver.

          Objective

          To uncover potential new somatic or germline drivers, we analyze a distinct cohort of patients with sporadic, very early–onset, and aggressive MTC.

          Methods

          Germline and somatic DNA exome sequencing was performed in 19 patients, previously tested negative for germline RET variants.

          Results

          Exome sequencing of 19 germline samples confirmed the absence of RET and identified an NF1 pathogenic variant in 1 patient. Somatic sequencing was successful in 15 tumors revealing RET variants in 80%, predominantly p.Met918Thr, which was associated with disease aggressiveness. In RET-negative tumors, pathogenic variants were found in HRAS and NF1. The NF1 germline and somatic variants were observed in a patient without a prior clinical diagnosis of neurofibromatosis type 1, demonstrating that the loss of heterozygosity of NF1 functions as a potential MTC driver. Somatic copy number alterations analysis revealed chromosomal alterations in 53.3% of tumors, predominantly in RET-positive cases, with losses in chromosomes 9 and 22 being the most prevalent.

          Conclusion

          This study reveals that within a cohort of early-onset nonhereditary MTC, RET remains the major driver gene. In RET-negative tumors, NF1 and RAS are drivers of sporadic MTC. In addition, in young patients without a RET germline mutation, a careful clinical evaluation with a consideration of germline NF1 gene analysis is ideal to exclude Neurofibromatosis type 1 (NF1).

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

          The American College of Medical Genetics and Genomics (ACMG) previously developed guidance for the interpretation of sequence variants. 1 In the past decade, sequencing technology has evolved rapidly with the advent of high-throughput next generation sequencing. By adopting and leveraging next generation sequencing, clinical laboratories are now performing an ever increasing catalogue of genetic testing spanning genotyping, single genes, gene panels, exomes, genomes, transcriptomes and epigenetic assays for genetic disorders. By virtue of increased complexity, this paradigm shift in genetic testing has been accompanied by new challenges in sequence interpretation. In this context, the ACMG convened a workgroup in 2013 comprised of representatives from the ACMG, the Association for Molecular Pathology (AMP) and the College of American Pathologists (CAP) to revisit and revise the standards and guidelines for the interpretation of sequence variants. The group consisted of clinical laboratory directors and clinicians. This report represents expert opinion of the workgroup with input from ACMG, AMP and CAP stakeholders. These recommendations primarily apply to the breadth of genetic tests used in clinical laboratories including genotyping, single genes, panels, exomes and genomes. This report recommends the use of specific standard terminology: ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’ to describe variants identified in Mendelian disorders. Moreover, this recommendation describes a process for classification of variants into these five categories based on criteria using typical types of variant evidence (e.g. population data, computational data, functional data, segregation data, etc.). Because of the increased complexity of analysis and interpretation of clinical genetic testing described in this report, the ACMG strongly recommends that clinical molecular genetic testing should be performed in a CLIA-approved laboratory with results interpreted by a board-certified clinical molecular geneticist or molecular genetic pathologist or equivalent.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013

            Thyroid cancer incidence has increased substantially in the United States over the last 4 decades, driven largely by increases in papillary thyroid cancer. It is unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid cancer mortality trends.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers

              The Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census (CGC) is an expert-curated description of the genes driving human cancer, used as a standard in cancer genetics across basic research, medical reporting and pharmaceutical development. After a major expansion and complete re-evaluation, the 2018 CGC describes in detail the effect of 719 cancer-driving genes. Recent expansion includes functional and mechanistic descriptions of how each gene contributes to disease generation, described in terms of the key cancer hallmarks and the impact of mutations on gene and protein function. These functional characteristics depict the extraordinary complexity of cancer biology, and suggest multiple cancer-related functions for many genes, which are often highly tissue- or tumour stage-dependent. The 2018 CGC encompasses a second-tier, describing an expanding list of genes (currently 145) from more recent cancer studies which show supportive but less detailed indications of a role in cancer.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Endocr Soc
                J Endocr Soc
                jes
                Journal of the Endocrine Society
                Oxford University Press (US )
                2472-1972
                06 April 2024
                30 March 2024
                30 March 2024
                : 8
                : 6
                : bvae059
                Affiliations
                Endocrinology, Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Laboratory of Molecular Genetics, Center for Translational Research in Oncology (LIM-24), Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Endocrine Oncology, University of Michigan Ann Arbor 48109, USA
                Pathology, Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Endocrinology, Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Laboratory of Molecular Genetics, Center for Translational Research in Oncology (LIM-24), Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre , Porto Alegre 90035-903, Brazil
                Endocrinology, Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Head and Neck Surgery, Hospital das Clínicas da Faculdade de Medicina da USP , São Paulo 05403-010, Brazil
                Thyroid Unit, Endocrine Division, Hospital de Clínicas de Porto Alegre , Porto Alegre 90035-903, Brazil
                Laboratory of Molecular Genetics, Center for Translational Research in Oncology (LIM-24), Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Genetic Endocrinology Unit, Cellular and Molecular Endocrinology Laboratory (LIM-25) Faculdade de Medicina da Universidade de São Paulo , São Paulo 01246-903, Brazil
                Endocrinology, Instituto do Câncer do Estado de São Paulo , São Paulo 01252-000, Brazil
                Author notes
                Correspondence: Luciana Audi Castroneves, MD, Instituto do Câncer do Estado de São Paulo, Praça Irmãos Karmann, 111, apto 171 A, Sumaré, São Paulo 01252-000, Brazil. Email: luciana.audi@ 123456hc.fm.usp.br .
                Author information
                https://orcid.org/0000-0002-2482-4675
                https://orcid.org/0000-0002-1730-9931
                https://orcid.org/0000-0002-8336-6432
                https://orcid.org/0000-0003-2340-3382
                https://orcid.org/0000-0002-5461-0301
                https://orcid.org/0000-0002-9832-0269
                https://orcid.org/0000-0003-2247-2538
                https://orcid.org/0000-0002-4186-5532
                https://orcid.org/0000-0002-0728-4937
                https://orcid.org/0000-0003-2567-7360
                https://orcid.org/0000-0002-7058-6321
                Article
                bvae059
                10.1210/jendso/bvae059
                11036102
                38655100
                5c96d72d-63c2-431e-93a9-a93c215d6789
                © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 December 2023
                : 21 March 2024
                : 23 April 2024
                Page count
                Pages: 8
                Funding
                Funded by: Fundação de Amparo à Pesquisa do Estado de São Paulo, DOI 10.13039/501100001807;
                Award ID: 2019/20300-5
                Categories
                Clinical Research Article
                AcademicSubjects/MED00250
                Jes/11

                medullary thyroid carcinoma,exome,chromosomal instability,nf1,ret

                Comments

                Comment on this article